Daewon Pharmaceutical Co., Ltd. (KRX:003220)

Market Cap	279.49B
Revenue (ttm)	603.74B
Net Income (ttm)	8.16B
Shares Out	21.43M
EPS (ttm)	381.36
PE Ratio	30.51
Forward PE	22.90
Dividend	300.00 (2.32%)
Ex-Dividend Date	Dec 27, 2024

Volume	9,807
Average Volume	17,419
Open	12,930
Previous Close	12,950
Day's Range	12,930 - 13,020
52-Week Range	12,370 - 16,780
Beta	0.26
RSI	37.80
Earnings Date	Aug 13, 2025

About Daewon Pharmaceutical

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a t...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1958
• Employees: 1,283
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 003220

Financial Performance

In 2024, Daewon Pharmaceutical's revenue was 598.16 billion, an increase of 13.51% compared to the previous year's 526.95 billion. Earnings were 14.21 billion, a decrease of -40.59%.